Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OCRX 3.89 +0.08 (2.10%)
price chart
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics Inc.: Ocera Therapeutics to Report Pipeline Progress and ...
PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter 2015 ...
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial ...
PALO ALTO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and ...
Ocera Therapeutics Well-Capitalized After The Merger
Ocera Therapeutics (NASDAQ:OCRX) announced the closing of a merger with Tranzyme on July 15. Immediately following the closing of the merger, certain of the Ocera investors invested approximately $20 million in the company through a private ...
Ocera Therapeutics' (OCRX) CEO Linda Grais on Q3 2014 Results - Earnings ...
Welcome to Ocera Therapeutics Q3 Earnings Call. This call is being webcast live on the Events page of the Investor section of Ocera's Web site at www.ocera.com. Pardon me its www.ocerainc.com. This call is the property of Ocera and any recording, ...
Related articles »  
Ocera Therapeutics (OCRX) Reports OCR-002 Phase 2a Missed Primary Endpoint
Ocera Therapeutics, Inc. (Nasdaq: OCRX) today announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company's drug candidate OCR-002 (ornithine phenylacetate) versus placebo in patients with upper ...
Ocera Announces Preliminary Topline Results From Phase 2a Investigator ...  GlobeNewswire (press release)
Mid-Day Changers: Krispy Kreme Doughnuts, Inc. (KKD), Ocera Therapeutics ...
Krispy Kreme Doughnuts, Inc. (KKD) of the Services sector has changed by 3.42% and at noon is trading with a volume of 357,283 shares with a volatility this week of 1.86%.
Ocera Therapeutics: A Potential Multibagger Biopharmaceutical Company
Ocera Therapeutics [Nasdaq: (NASDAQ:OCRX)] announced the initiation of its phase 2b double blind, controlled, randomized clinical trial in early January 2014.
Related articles »  
Ocera Therapeutics Announces Completion of Merger With Tranzyme
SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera"), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc. (Nasdaq:TZYM) ("Tranzyme") today announced ...
Related articles »  
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue?
Ocera Therapeutics Inc (OCRX - Snapshot Report) has been on the move lately as the stock has risen by 8.9% in the past four weeks, and it is currently trading well above its 20-Day SMA.